Pirtobrutinib Drug Interaction Study with Midazolam in Healthy Subjects

Phase 1, open-label, single-arm trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration of Midazolam and Its Metabolite Following Oral Dose at Day 17, Area Under the Concentration-Time From Time 0 Extrapolated To Infinity of Midazolam and Its Metabolite Following Oral Dose at Day 17 and 4 more. Started Sep 2020; status: completed.